The trip is the therapy: psilocybin’s brain changes outlast the psychedelic experience
For years, one of the central questions in psychedelic research has been whether the subjective experience, the “trip” itself, is essential to therapeutic outcomes or merely a side effect that could be eliminated with a better drug. A new study from the University of California, San Francisco and Imperial College London provides the clearest evidence yet that the psychedelic experience is not incidental. It is the mechanism.
Published in Nature Communications (DOI: 10.1038/s41467-026-71962-3), the study followed 28 healthy adults with no prior psychedelic use through two experimental sessions: a placebo dose (1 mg of psilocybin) and, one month later, a full psychedelic dose (25 mg). The within-subject design allowed each participant to serve as their own control, a methodological strength that avoids the confounding variables that plague between-subject comparisons.
Entropy as a measure of mental flexibility
Within 60 minutes of the 25 mg dose, electroencephalography showed a marked increase in brain entropy, a measure of the diversity and unpredictability of neural activity. High-entropy brain states are associated with greater cognitive flexibility: the ability to shift between different modes of thinking, to break free of habitual patterns, and to form novel associations.
The entropy increase was not uniform. Participants who showed the largest entropy spikes during the trip reported the highest levels of emotional insight the following day. The chain of effect was measurable: greater entropy led to greater insight, and greater insight predicted improvements in well-being at both two weeks and four weeks after the session.
“The data shows that such experiences of psychological insight relate to an entropic quality of brain activity and how both are involved in causing subsequent improvements in mental health,” said Robin Carhart-Harris, the study’s senior author and a professor at UCSF. “It suggests that the trip, and its correlates in the brain, is a key component of how psychedelic therapy works.”
Structural changes that last
The most surprising finding came from brain imaging performed one month after the dose. Diffusion tensor imaging (DTI), which measures the integrity of white matter tracts, revealed denser, more intact neural pathways in participants who had received psilocybin compared with their baseline scans. The pattern was the reverse of what is typically seen in age-related neural decline.
The researchers caution that these structural findings are preliminary. “Additional studies are needed to determine exactly what these structural findings mean,” they note. But the observation that a single pharmacological intervention can produce measurable changes in brain structure that persist for at least a month is, by their own description, a “previously unseen indication” of lasting psychedelic effects.
The structural changes correlated with behavioral measures. Participants showed improved cognitive flexibility, the ability to adapt to changing information and rules, that persisted at the one-month mark, suggesting the structural reorganization may have functional consequences.
The insight–well-being link
Every one of the 28 participants rated the 25 mg experience as either the single most unusual state of consciousness they had ever encountered (27 of 28) or among the top five (1 of 28). Subjectively, the experience was transformative. But the study’s design allows the researchers to distinguish between the experience itself and its downstream effects on well-being.
The statistical pathway runs from dose, to entropy, to insight, to well-being. Participants whose brains showed the most entropy during the trip reported the deepest insights the next day. Those insights, in turn, predicted improvements in measures of optimism, coping, and handling problems that lasted for the full month of follow-up.
This suggests that the therapeutic mechanism of psilocybin is not pharmacological in the conventional sense, not simply a matter of receptor binding and downstream signaling, but psychological: the drug creates a state of neural flexibility that enables the person to revise entrenched patterns of thinking, and it is that revision, not the drug itself, that produces lasting change.
“Psilocybin seems to loosen up stereotyped patterns of brain activity and give people the ability to revise entrenched patterns of thought,” said Taylor Lyons, the first author.
Implications for clinical use
The findings have practical consequences for how psychedelic therapy is administered. If the trip is essential, then efforts to develop non-hallucinogenic psychedelic analogs, drugs that produce the molecular effects without the subjective experience, may be pursuing a flawed target. The subjective experience may be the active ingredient.
The study also provides a neural marker, brain entropy measured by EEG, that could help clinicians calibrate dosing. Enough drug to produce a meaningful entropy shift, but not more than necessary, would optimize the balance between therapeutic effect and unnecessary intensity.
All participants in this study were healthy. Whether the same mechanisms operate in clinical populations, people with depression, anxiety, or addiction, is the next question. But the study establishes that for healthy brains, the psychedelic state leaves a measurable trace that outlasts the experience itself.
Reference: Lyons et al., “Human brain changes after first psilocybin use,” Nature Communications (2026). DOI: 10.1038/s41467-026-71962-3.